Curcumin and dimethoxycurcumin induced epigenetic changes in leukemia cells

Pharmaceutical Research

Volumn 32, Issue 3, 2015, Pages 863-875

  Hassan, Hazem E ^a   Carlson, Samuel ^b   Abdallah, Inas ^a   Buttolph, Thomm ^c   Glass, Karen C ^b   Fandy, Tamer E ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

curcumin; dimethoxycurcumin; DNA methylation; DNA pyrosequencing; histone methylation

Indexed keywords

ANTILEUKEMIC AGENT; CURCUMIN; DIMETHOXYCURCUMIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; ENZYME; HISTONE H3; PROTEIN P15; PROTEIN TET1; PROTEIN TET2; PROTEIN TET3; UNCLASSIFIED DRUG; UVOMORULIN; ANTINEOPLASTIC AGENT; HISTONE;

APOPTOSIS; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DNA METHYLATION; DRUG METABOLISM; DRUG STABILITY; EPIGENETICS; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; LEUKEMIA; METABOLISM; METHYLATION; PATHOLOGY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOTRANSFORMATION; CELL LINE, TUMOR; CURCUMIN; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; EPIGENESIS, GENETIC; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; HUMANS; LEUKEMIA; METHYLATION; MICROSOMES, LIVER; PROMOTER REGIONS, GENETIC; TIME FACTORS;

EID: 84923014709     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1502-4     Document Type: Article

References (43)

1. Shankar S, Srivastava RK. Bax and Bak genes are essential for maximum apoptotic response by curcumin, a polyphenolic compound and cancer chemopreventive agent derived from turmeric. Curcuma longa Carcinog. 2007;28(6):1277-86.
2. Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. Biofactors. 2013;39(1):69-77.
3. Bukhari SN, Franzblau SG, Jantan I, Jasamai M. Current prospects of synthetic curcumin analogs and chalcone derivatives against mycobacterium tuberculosis. Med Chem. 2013;9(7):897-903.
4. Ou JL, Mizushina Y, Wang SY, Chuang DY, Nadar M, Hsu WL. Structure-activity relationship analysis of curcumin analogues on anti-influenza virus activity. FEBS J. 2013;280(22):5829-40.
5. Gazal M, Valente MR, Acosta BA, Kaufmann FN, Braganhol E, Lencina CL, et al. Neuroprotective and antioxidant effects of curcumin in a ketamine-induced model of mania in rats. Eur J Pharmacol. 2014;724:132-9.
6. Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer. 2008;7:16.
7. Srivastava RK, Chen Q, Siddiqui I, Sarva K, Shankar S. Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle. 2007;6(23):2953-61.
8. Shankar S, Chen Q, Sarva K, Siddiqui I, Srivastava RK. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J Mol Signal. 2007;2:10.
9. Qiu P, Xu L, Gao L, Zhang M, Wang S, Tong S, et al. Exploring pyrimidine-substituted curcumin analogues: design, synthesis and effects on EGFR signaling. Bioorg Med Chem. 2013;21(17):5012-20.
10. Chakraborti S, Dhar G, Dwivedi V, Das A, Poddar A, Chakraborti G, et al. Stable and potent analogues derived from the modification of the dicarbonyl moiety of curcumin. Biochemistry. 2013;52(42):7449-60.
11. Chen WF, Deng SL, Zhou B, Yang L, Liu ZL. Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. Free Radic Biol Med. 2006;40(3):526-35.
12. Liu H, Liu YZ, Zhang F, Wang HS, Zhang G, Zhou BH, Zuo YL, Cai SH, Bu XZ, Du J. Identification of potential pathways involved in the induction of cell cycle arrest and apoptosis by a new 4-arylidene curcumin analogue T63 in lung cancer cells: a comparative proteomic analysis. Mol Biosyst. 2014.
13. Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, et al. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett. 2013;341(2):195-203.
14. Chen C, Liu Y, Chen Y, Xu J. C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFkappaB in colon cancer cells and xenograft tumors. Cancer Biol Ther. 2011;12(9):797-807.
15. Chen Y, Shu W, Chen W, Wu Q, Liu H, Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol. 2007;101(6):427-33.
16. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7(3):464-73.
17. Yu J, Peng Y, Wu LC, Xie Z, Deng Y, Hughes T, et al. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS One. 2013;8(2):e55934.
18. Du L, Xie Z, Wu LC, Chiu M, Lin J, Chan KK, et al. Reactivation of RASSF1A in breast cancer cells by curcumin. Nutr Cancer. 2012;64(8):1228-35.
19. Parashar G, Parashar NC, Capalash N. Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line. Mol Cell Biochem. 2012;365(1-2):29-35.
20. Shu L, Khor TO, Lee JH, Boyanapalli SS, Huang Y, Wu TY, et al. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPPS J. 2011;13(4):606-14.
21. Khor TO, Huang Y, Wu TY, Shu L, Lee J, Kong AN. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem Pharmacol. 2011;82(9):1073-8.
22. Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett. 2009;19(3):706-9.
23. Link A, Balaguer F, Shen Y, Lozano JJ, Leung HC, Boland CR, et al. Curcumin modulates DNA methylation in colorectal cancer cells. PLoS One. 2013;8(2):e57709.
24. Medina-Franco JL, Lopez-Vallejo F, Kuck D, Lyko F. Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Mol Divers. 2011;15(2):293-304.
25. Fandy TE, Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res. 2014;20(5):1249-58.
26. Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, et al. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene. 2008;27(25):3615-23.
27. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc. 2007;2(9):2265-75.
28. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004;32(3):e38.
29. Moiseeva EP, Almeida GM, Jones GD, Manson MM. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther. 2007;6(11):3071-9.
30. Liu HS, Ke CS, Cheng HC, Huang CY, Su CL. Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A. Mol Pharmacol. 2011;80(4):638-46.
31. Fandy TE. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem. 2009;16(17):2075-85.
32. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114(13):2764-73.
33. Migheli F, Stoccoro A, Coppede F, Wan Omar WA, Failli A, Consolini R, et al. Comparison study of MS-HRM and pyrosequencing techniques for quantification of APC and CDKN2A gene methylation. PLoS One. 2013;8(1):e52501.
34. Easwaran HP, Schermelleh L, Leonhardt H, Cardoso MC. Replication-independent chromatin loading of Dnmt1 during G2 and M phases. EMBO Rep. 2004;5(12):1181-6.
35. Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65(14):6305-11.
36. Sarris M, Nikolaou K, Talianidis I. Context-specific regulation of cancer epigenomes by histone and transcription factor methylation. Oncogene. 2014;33(10):1207-17.
37. Tamvakopoulos C, Dimas K, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, et al. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res. 2007;13(4):1269-77.
38. Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA. Evaluation of liposomal curcumin cytochrome p450 metabolism. Anticancer Res. 2010;30(3):811-4.
39. Liu Z, Liu S, Xie Z, Blum W, Perrotti D, Paschka P, et al. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res. 2007;35(5):e31.
40. Mohr F, Dohner K, Buske C, Rawat VP. TET genes: new players in DNA demethylation and important determinants for stemness. Exp Hematol. 2011;39(3):272-81.
41. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000;60(24):6890-4.
42. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006;2(3):e40.
43. Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, et al. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res. 2012;72(5):1170-81.